Cargando…

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery

BACKGROUND AND PURPOSE: Unnecessary surgery can be avoided, and more appropriate treatment plans can be developed for patients if the efficacy of neoadjuvant immunochemotherapy for esophageal cancer (EC) can be predicted before surgery. The purpose of this study was to evaluate the ability of machin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Kaiyuan, Li, Yuetong, Wang, Zhulin, Huang, Chunyao, Sun, Shaowu, Liu, Xu, Fan, Wenbo, Zhang, Guoqing, Li, Xiangnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213404/
https://www.ncbi.nlm.nih.gov/pubmed/37251937
http://dx.doi.org/10.3389/fonc.2023.1131883
_version_ 1785047615427051520
author Li, Kaiyuan
Li, Yuetong
Wang, Zhulin
Huang, Chunyao
Sun, Shaowu
Liu, Xu
Fan, Wenbo
Zhang, Guoqing
Li, Xiangnan
author_facet Li, Kaiyuan
Li, Yuetong
Wang, Zhulin
Huang, Chunyao
Sun, Shaowu
Liu, Xu
Fan, Wenbo
Zhang, Guoqing
Li, Xiangnan
author_sort Li, Kaiyuan
collection PubMed
description BACKGROUND AND PURPOSE: Unnecessary surgery can be avoided, and more appropriate treatment plans can be developed for patients if the efficacy of neoadjuvant immunochemotherapy for esophageal cancer (EC) can be predicted before surgery. The purpose of this study was to evaluate the ability of machine learning models based on delta features of immunochemotherapy CT images to predict the efficacy of neoadjuvant immunochemotherapy in patients with esophageal squamous cell carcinoma (ESCC) compared with machine learning models based solely on postimmunochemotherapy CT images. MATERIALS AND METHODS: A total of 95 patients were enrolled in our study and randomly divided into a training group (n = 66) and test group (n = 29). We extracted preimmunochemotherapy radiomics features from preimmunochemotherapy enhanced CT images in the preimmunochemotherapy group (pregroup) and postimmunochemotherapy radiomics features from postimmunochemotherapy enhanced CT images in the postimmunochemotherapy group (postgroup). We then subtracted the preimmunochemotherapy features from the postimmunochemotherapy features and obtained a series of new radiomics features that were included in the delta group. The reduction and screening of radiomics features were carried out by using the Mann-Whitney U test and LASSO regression. Five pairwise machine learning models were established, the performance of which was evaluated by receiver operating characteristic (ROC) curve and decision curve analyses. RESULTS: The radiomics signature of the postgroup was composed of 6 radiomics features; that of the delta-group was composed of 8 radiomics features. The area under the ROC curve (AUC) of the machine learning model with the best efficacy was 0.824 (0.706-0.917) in the postgroup and 0.848 (0.765-0.917) in the delta group. The decision curve showed that our machine learning models had good predictive performance. The delta group performed better than the postgroup for each corresponding machine learning model. CONCLUSION: We established machine learning models that have good predictive efficacy and can provide certain reference values for clinical treatment decision-making. Our machine learning models based on delta imaging features performed better than those based on single time-stage postimmunochemotherapy imaging features.
format Online
Article
Text
id pubmed-10213404
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102134042023-05-27 Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery Li, Kaiyuan Li, Yuetong Wang, Zhulin Huang, Chunyao Sun, Shaowu Liu, Xu Fan, Wenbo Zhang, Guoqing Li, Xiangnan Front Oncol Oncology BACKGROUND AND PURPOSE: Unnecessary surgery can be avoided, and more appropriate treatment plans can be developed for patients if the efficacy of neoadjuvant immunochemotherapy for esophageal cancer (EC) can be predicted before surgery. The purpose of this study was to evaluate the ability of machine learning models based on delta features of immunochemotherapy CT images to predict the efficacy of neoadjuvant immunochemotherapy in patients with esophageal squamous cell carcinoma (ESCC) compared with machine learning models based solely on postimmunochemotherapy CT images. MATERIALS AND METHODS: A total of 95 patients were enrolled in our study and randomly divided into a training group (n = 66) and test group (n = 29). We extracted preimmunochemotherapy radiomics features from preimmunochemotherapy enhanced CT images in the preimmunochemotherapy group (pregroup) and postimmunochemotherapy radiomics features from postimmunochemotherapy enhanced CT images in the postimmunochemotherapy group (postgroup). We then subtracted the preimmunochemotherapy features from the postimmunochemotherapy features and obtained a series of new radiomics features that were included in the delta group. The reduction and screening of radiomics features were carried out by using the Mann-Whitney U test and LASSO regression. Five pairwise machine learning models were established, the performance of which was evaluated by receiver operating characteristic (ROC) curve and decision curve analyses. RESULTS: The radiomics signature of the postgroup was composed of 6 radiomics features; that of the delta-group was composed of 8 radiomics features. The area under the ROC curve (AUC) of the machine learning model with the best efficacy was 0.824 (0.706-0.917) in the postgroup and 0.848 (0.765-0.917) in the delta group. The decision curve showed that our machine learning models had good predictive performance. The delta group performed better than the postgroup for each corresponding machine learning model. CONCLUSION: We established machine learning models that have good predictive efficacy and can provide certain reference values for clinical treatment decision-making. Our machine learning models based on delta imaging features performed better than those based on single time-stage postimmunochemotherapy imaging features. Frontiers Media S.A. 2023-05-12 /pmc/articles/PMC10213404/ /pubmed/37251937 http://dx.doi.org/10.3389/fonc.2023.1131883 Text en Copyright © 2023 Li, Li, Wang, Huang, Sun, Liu, Fan, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Kaiyuan
Li, Yuetong
Wang, Zhulin
Huang, Chunyao
Sun, Shaowu
Liu, Xu
Fan, Wenbo
Zhang, Guoqing
Li, Xiangnan
Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
title Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
title_full Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
title_fullStr Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
title_full_unstemmed Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
title_short Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
title_sort delta-radiomics based on ct predicts pathologic complete response in escc treated with neoadjuvant immunochemotherapy and surgery
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213404/
https://www.ncbi.nlm.nih.gov/pubmed/37251937
http://dx.doi.org/10.3389/fonc.2023.1131883
work_keys_str_mv AT likaiyuan deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT liyuetong deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT wangzhulin deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT huangchunyao deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT sunshaowu deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT liuxu deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT fanwenbo deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT zhangguoqing deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery
AT lixiangnan deltaradiomicsbasedonctpredictspathologiccompleteresponseinescctreatedwithneoadjuvantimmunochemotherapyandsurgery